HONOLULU, July 14 /PRNewswire/ — EnVivo
Pharmaceuticals today announced at the Alzheimer’s Association 2010
International Conference on Alzheimer’s Disease (ICAD) results from
its proprietary gamma-secretase modulator (GSM) pre-clinical study.
In a transgenic mouse model, EnVivo’s EVP-0015962 reduced
amyloid plaque buildup which is believed to be a cause of
Alzheimer’s disease, reversed behavioral deficits and reduced brain
inflammation associated with Alzheimer’s disease.
EVP-0015962 is a proprietary small molecule compound that
belongs to a new generation of potential Alzheimer’s drugs known as
gamma-secretase modulators. EVP-0015962 selectively inhibits
the production of the toxic aggregated amyloid AB42 peptide without
affecting the total amount of AB. As EVP-0015962 does not
affect other gamma secretase substrates required for normal
function, such as Notch, it is predicted to slow the progression of
Alzheimer’s disease by reducing the disease-associated toxic AB42
In its study, EnVivo was able to show that EVP-0015962
significantly reduced the production of total amyloid load as
measured by plaque count, surface area and aggregated AB in the
brains of transgenic mice after 12 months of daily oral
administration. In the same model, mice developed deficits in
the hippocampal memory task known as contextual fear conditioning.
Chronic dosing with EVP-0015962 reversed these deficits
returning the cognitive function to normal levels. In
addition, EVP-0015962 reduced the amount of brain inflammation
associated with amyloid plaque buildup in these animals.
These findings demonstrate continued positive effects in
transgenic Alzheimer’s animals with EVP-0015962. Given the
multiple positive results from this and previous studies, EnVivo is